Literature DB >> 7817972

Estimation of current human immunodeficiency virus incidence rates from a cross-sectional survey using early diagnostic tests.

R Brookmeyer1, T C Quinn.   

Abstract

In sharp contrast to the considerable worldwide epidemiologic data available on acquired immunodeficiency syndrome incidence and human immunodeficiency virus (HIV) seroprevalence, there is relatively little information about current levels of HIV incidence rates. The authors suggest a novel approach for estimating current HIV incidence rates based on a single cross-sectional survey and on an epidemiologic model. The approach is based on diagnostic tests for HIV p24 antigen to identify individuals in the preantibody or window period (time between exposure to HIV and appearance of detectable HIV antibodies). Individuals in the preantibody period are likely to have been infected very recently because the duration of the preantibody period is relatively short. The authors report data on the duration of p24 antigenemia prior to HIV seroconversion. This duration together with the prevalence of p24 antigenemia obtained from a cross-sectional survey are used in an epidemiologic model to estimate current incidence rates. This approach of estimating incidence rates may be especially useful in developing countries and high-risk populations in which it is difficult to follow cohorts to identify seroconverters, and in the design of vaccine efficacy studies in which current incidence rates are crucial for calculating sample sizes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7817972     DOI: 10.1093/oxfordjournals.aje.a117404

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  67 in total

1.  Seroincidence of recent human immunodeficiency virus type 1 infections in China.

Authors:  Yao Xiao; Yan Jiang; Jigang Feng; Wenyan Xu; Minjie Wang; Ellen Funkhouser; Sten H Vermund; Yujiang Jia
Journal:  Clin Vaccine Immunol       Date:  2007-08-01

2.  Nonparametric incidence estimation from prevalent cohort survival data.

Authors:  Marco Carone; Masoud Asgharian; Mei-Cheng Wang
Journal:  Biometrika       Date:  2012-07-24       Impact factor: 2.445

3.  Short Communication: Defining optimality of a test for recent infection for HIV incidence surveillance.

Authors:  Reshma Kassanjee; Thomas A McWalter; Alex Welte
Journal:  AIDS Res Hum Retroviruses       Date:  2013-10-26       Impact factor: 2.205

4.  Relating recent infection prevalence to incidence with a sub-population of assay non-progressors.

Authors:  Thomas Andrew McWalter; Alex Welte
Journal:  J Math Biol       Date:  2009-07-25       Impact factor: 2.259

5.  Lower-sensitivity and avidity modifications of the vitros anti-HIV 1+2 assay for detection of recent HIV infections and incidence estimation.

Authors:  Sheila M Keating; Debra Hanson; Mila Lebedeva; Oliver Laeyendecker; N'ko L Ali-Napo; S Michele Owen; Susan L Stramer; Richard D Moore; Philip J Norris; Michael P Busch
Journal:  J Clin Microbiol       Date:  2012-10-03       Impact factor: 5.948

6.  Immune responses in Ugandan women infected with subtypes A and D HIV using the BED capture immunoassay and an antibody avidity assay.

Authors:  Andrew F Longosz; Charles S Morrison; Pai-Lien Chen; Eric Arts; Immaculate Nankya; Robert A Salata; Veronica Franco; Thomas C Quinn; Susan H Eshleman; Oliver Laeyendecker
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-01       Impact factor: 3.731

7.  Selection of recombinant, library-derived antibody fragments against p24 for human immunodeficiency virus type 1 diagnostics.

Authors:  H J de Haard; B Kazemier; M J Koolen; L J Nijholt; R H Meloen; B van Gemen; H R Hoogenboom; J W Arends
Journal:  Clin Diagn Lab Immunol       Date:  1998-09

8.  Cross-Sectional HIV Incidence Estimation with Missing Biomarkers.

Authors:  Doug Morrison; Oliver Laeyendecker; Jacob Konikoff; Ron Brookmeyer
Journal:  Stat Commun Infect Dis       Date:  2018-07-31

9.  Short communication: effect of short-course antenatal zidovudine and single-dose nevirapine on the BED capture enzyme immunoassay levels in HIV type 1 subtype C infection.

Authors:  Rui Wang; Jia Weng; Sikhulile Moyo; Debanjan Pain; Christopher D Barr; Dorcas Maruapula; Dineo Mongwato; Joseph Makhema; Vladimir Novitsky; M Essex
Journal:  AIDS Res Hum Retroviruses       Date:  2013-04-19       Impact factor: 2.205

10.  Estimation of HIV incidence in the United States.

Authors:  H Irene Hall; Ruiguang Song; Philip Rhodes; Joseph Prejean; Qian An; Lisa M Lee; John Karon; Ron Brookmeyer; Edward H Kaplan; Matthew T McKenna; Robert S Janssen
Journal:  JAMA       Date:  2008-08-06       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.